Zacks Research Weighs in on Omnicell, Inc.’s Q1 2025 Earnings (NASDAQ:OMCL)

Omnicell, Inc. (NASDAQ:OMCLFree Report) – Analysts at Zacks Research increased their Q1 2025 EPS estimates for shares of Omnicell in a research note issued on Tuesday, October 1st. Zacks Research analyst U. Biswas now expects that the company will earn $0.14 per share for the quarter, up from their prior estimate of $0.13. The consensus estimate for Omnicell’s current full-year earnings is $0.64 per share. Zacks Research also issued estimates for Omnicell’s Q1 2026 earnings at $0.29 EPS and FY2026 earnings at $0.73 EPS.

Omnicell (NASDAQ:OMCLGet Free Report) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.37. The firm had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The company’s quarterly revenue was down 7.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.29 EPS.

A number of other research analysts have also weighed in on the stock. Benchmark reaffirmed a “buy” rating and issued a $38.00 price target on shares of Omnicell in a research note on Monday, July 15th. Bank of America lifted their price objective on shares of Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Wells Fargo & Company boosted their target price on shares of Omnicell from $26.00 to $30.00 and gave the company an “equal weight” rating in a research report on Friday, August 2nd. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Thursday, September 19th. Finally, Barclays raised Omnicell from an “underweight” rating to an “equal weight” rating and upped their price objective for the company from $26.00 to $39.00 in a research note on Friday, August 2nd. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $37.83.

View Our Latest Analysis on Omnicell

Omnicell Stock Up 2.1 %

Omnicell stock opened at $42.39 on Thursday. The company’s 50 day simple moving average is $42.08 and its 200 day simple moving average is $33.28. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $46.05. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of -92.15, a PEG ratio of 47.43 and a beta of 0.83. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.45 and a quick ratio of 2.22.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in Omnicell by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock worth $165,200,000 after buying an additional 80,312 shares during the last quarter. Mutual of America Capital Management LLC raised its holdings in shares of Omnicell by 197.9% during the first quarter. Mutual of America Capital Management LLC now owns 124,600 shares of the company’s stock valued at $3,642,000 after acquiring an additional 82,774 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Omnicell by 61.3% during the second quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock valued at $16,240,000 after acquiring an additional 228,093 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Omnicell during the first quarter valued at approximately $684,000. Finally, Cadian Capital Management LP bought a new position in shares of Omnicell during the fourth quarter valued at approximately $2,446,000. Institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

(Get Free Report)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Further Reading

Earnings History and Estimates for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.